ORPHAGEN PHARMACEUTICALS AWARDED SBIR PHASE II GRANT TO DEVELOP A FIRST-IN-CLASS DRUG FOR ADRENOCORTICAL CANCER
Orphagen Pharmaceuticals, a privately-held pharmaceutical company, announced today that the National Cancer Institute (NCI) has indicated its intention to award the company $2.0 million under the Small Business Innovation Research (SBIR) program to support preclinical...
Orphagen Pharmaceuticals Announces Promotion of Paul Crowe to Vice President, Drug Discovery
Orphagen Pharmaceuticals, a preclinical stage biopharmaceutical company focused on discovering and developing first-in-class therapeutics for cancer and inflammatory disease, announced the promotion of Paul Crowe to Vice President, Drug Discovery, effective June 30,...
ORPHAGEN PHARMACEUTICALS TO PRESENT PRECLINICAL DATA FOR OR-449 AT THE ENDOCRINE SOCIETY’S 2021 ANNUAL MEETING
Orphagen Pharmaceuticals, an early-stage biopharmaceutical company focused on developing and commercializing novel therapies for cancer and other serious diseases with significant unmet need, today announced that data from its preclinical program to develop OR-449 for...
ORPHAGEN PHARMACEUTICALS AWARDED SBIR PHASE II GRANT TO INVESTIGATE RETINOIC TARGETS FOR MALE CONTRACEPTIVES
Orphagen Pharmaceuticals, a privately-held pharmaceutical company, announced today that the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) has awarded the company $1.8 million under the Small Business Innovation Research (SBIR)...
Orphagen Pharmaceuticals and the Pharmaceutical Division of Japan Tobacco Enter into a Collaborative Agreement
San Diego, June 1, 2018 – Orphagen Pharmaceuticals, a privately held pharmaceutical company, announced today that it has entered into a collaborative agreement with the pharmaceutical division of Japan Tobacco Inc. (JT) to discover, develop and commercialize drugs...
Orphagen Pharmaceuticals Awarded Additional US Patent for Modulators of Orphan Nuclear Receptor ROR-gamma
San Diego, June 1, 2018 – Orphagen Pharmaceuticals, a privately held pharmaceutical company, announced today that it has been awarded US patent 9,657,053 for the use of small molecule ligands to inhibit retinoid-related orphan receptor gamma...
ORPHAGEN PARTNER, JAPAN TOBACCO, INITIATES A PHASE I CLINICAL TRIAL OF A NOVEL SMALL MOLECULE THERAPEUTIC FOR AUTOIMMUNE AND ALLERGIC DISEASES
Orphagen Pharmaceuticals, Inc., a privately held company, announced today that its partner, Japan Tobacco Inc. (“JT”), has entered Phase I clinical trials with an oral small molecule, JTE-451, for treatment of autoimmune and allergic diseases. This is a major...
Orphagen Pharmaceuticals Presents Pharmacology of ROR-beta Antagonists at the Keystone Symposium on Nuclear Receptors
Orphagen Pharmaceuticals, a privately-held emerging pharmaceutical company, described for the first time properties of small molecule antagonists to ROR-beta, an orphan nuclear receptor, at the Keystone Symposium on Nuclear Receptors taking place January 10-14 at...
Orphagen Pharmaceuticals Awarded Federal Funding to Investigate a Novel Drug Discovery Target for Sickle Cell Disease
Orphagen Pharmaceuticals, a privately-held pharmaceutical company, announced today that the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health has awarded the company a highly competitive Phase 1 Small Business Innovative Research...
Orphagen Pharmaceuticals Awarded $224,954 to Investigate an Orphan Nuclear Receptor as Novel Drug Discovery Target for Cancer Immunotherapy
Orphagen Pharmaceuticals, a privately-held pharmaceutical company, announced today that the National Institutes of Health (NIH) National Cancer Institute (NCI) has awarded the company $224,954 under the Small Business Innovative Research (SBIR) program to identify...